- Home
- Journals
- Case Reports
- Products & Services
- Events
- Media Partners
Cappella Medical Devices
- Home
- Sideguard®
- Congresses/Events
Home
Cappella Medical Devices
Cappella, Inc. – a medical device company specialising in cardiovascular innovations –
has developed the Sideguard® Coronary Sidebranch Stent & Delivery System, offering
interventional cardiologists a novel solution for the treatment of coronary bifurcation disease.
Sideguard® – Cappella’s initial product – consists of a uniquely designed self-expanding nitinol coronary stent that makes use of a novel, balloon-catheter, split-sheath delivery system. Both the stent and the delivery system were developed by Cappella Medical Devices Ltd., the R&D and manufacturing subsidiary of Cappella, Inc.
CE-marked in April 2009, Cappella’s Sideguard® offers a new, simple and effective option for treating bifurcation disease, with a focus on treating the sidebranch of the diseased coronary artery first, rather than the main vessel. Moreover, the Sideguard® system allows the preferred stent of choice for the main vessel.
The Sideguard® stent is used in combination with a novel, low-profile balloon-catheter delivery system, which enables straightforward, rapid-exchange delivery and precise stent placement at the sidebranch ostium. During positioning, a sheath encloses the stent; however, once the stent is in place, the delivery system balloon is inflated, and in doing so, the sheath is split and the stent released. The delivery system is then withdrawn, leaving the stent in place. This proprietary split-sheath technology prevents the stent jumping at delivery and ensures accurate deployment of the device.
Bifurcation procedures are complicated, not least owing to the complex and variable anatomy of the coronary ostia. The Sideguard® stent itself is uniquely designed to conform to the anatomy of the sidebranch ostium, and while the elastic property of nitinol enables the stent to self expand so as to adapt to the various ostial morphologies, the mechanical property of nitinol sustains continuous wall apposition and scaffolding. The stent is thus able to dynamically appose the full lumen of the sidebranch, including the ostium. This dynamic apposition results in continuous contact between the stent and the vessel wall, as well as arterial expansion (positive remodelling) over time.
The Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a dynamic new option for treating bifurcation disease. This unique product demonstrates that good product design is able to provide benefits that can be seen in the clinic.
Sideguard® – Cappella’s initial product – consists of a uniquely designed self-expanding nitinol coronary stent that makes use of a novel, balloon-catheter, split-sheath delivery system. Both the stent and the delivery system were developed by Cappella Medical Devices Ltd., the R&D and manufacturing subsidiary of Cappella, Inc.
CE-marked in April 2009, Cappella’s Sideguard® offers a new, simple and effective option for treating bifurcation disease, with a focus on treating the sidebranch of the diseased coronary artery first, rather than the main vessel. Moreover, the Sideguard® system allows the preferred stent of choice for the main vessel.
The Sideguard® stent is used in combination with a novel, low-profile balloon-catheter delivery system, which enables straightforward, rapid-exchange delivery and precise stent placement at the sidebranch ostium. During positioning, a sheath encloses the stent; however, once the stent is in place, the delivery system balloon is inflated, and in doing so, the sheath is split and the stent released. The delivery system is then withdrawn, leaving the stent in place. This proprietary split-sheath technology prevents the stent jumping at delivery and ensures accurate deployment of the device.
Bifurcation procedures are complicated, not least owing to the complex and variable anatomy of the coronary ostia. The Sideguard® stent itself is uniquely designed to conform to the anatomy of the sidebranch ostium, and while the elastic property of nitinol enables the stent to self expand so as to adapt to the various ostial morphologies, the mechanical property of nitinol sustains continuous wall apposition and scaffolding. The stent is thus able to dynamically appose the full lumen of the sidebranch, including the ostium. This dynamic apposition results in continuous contact between the stent and the vessel wall, as well as arterial expansion (positive remodelling) over time.
The Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a dynamic new option for treating bifurcation disease. This unique product demonstrates that good product design is able to provide benefits that can be seen in the clinic.
Contact Details
Unit 3 Ballybrit Business ParkGalway
Ireland
Tel:
+353 (0) 91 758939
Fax: +353 (0) 91 758930
contact: info@cappella.ie
website: www.cappella-med.com
Fax: +353 (0) 91 758930
contact: info@cappella.ie
website: www.cappella-med.com
Keywords:
coronary stent, invasive cardiology, acapella medical device, coronary arteries, drug eluting stent, stent restenosis, eluting coronary stent, stent thrombosis
Related categories:
Device Companiescoronary stent, invasive cardiology, acapella medical device, coronary arteries, drug eluting stent, stent restenosis, eluting coronary stent, stent thrombosis
Sideguard®
Sideguard®
Cappella’s Sideguard® technology offers interventional cardiologists a straightforward, effective, and easy-to-use solution that preserves the sidebranch of diseased coronary arteries by protecting the ostium while minimizing plaque shift. The Sideguard delivery system features a proprietary split-sheath, balloon-released, technology that ensures precise placement on the ostial borderline. The Sideguard self-expanding nitinol stent promotes continuous wall apposition and positive remodeling and its unique trumpet-shaped design conforms to varying characteristics of the sidebranch ostium.
Click here for more information on Sideguard®
Congresses/Events
Events/Congresses that Cappella will be attending -
German Cardiac Society Meeting
Euro PCR
SOLACI 2011
TCT 2011